LOAN AND SECURITY AGREEMENTLoan and Security Agreement • November 4th, 2015 • Visterra, Inc. • Pharmaceutical preparations
THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of September 9, 2014 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender and SQUARE 1 BANK, a North Carolina banking corporation with an office located at 406 Blackwell Street, Suite 240, Durham, NC 27701 (“Bank” or “Square 1”) (each a “Lender” and collectively, the “Lenders”), and VISTERRA, Inc., a Delaware corporation with offices located at One Kendall Square, Suite B3301, Cambridge, MA 02139 (“Borrower”), provides the terms on which the Lenders shall lend to Borrower and Borrower shall repay the Lenders. The parties agree as foll
VISTERRA, INC. Nonstatutory Stock Option Agreement Granted Under 2008 Stock Incentive PlanNonstatutory Stock Option Agreement • November 4th, 2015 • Visterra, Inc. • Pharmaceutical preparations
VISTERRA, INC. Incentive Stock Option Agreement Granted Under 2008 Stock Incentive PlanIncentive Stock Option Agreement • November 4th, 2015 • Visterra, Inc. • Pharmaceutical preparations
AMENDED AND RESTATED SERIES B CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT VISTERRA, INC. September 12, 2014Series B Convertible Preferred Stock Purchase Agreement • November 4th, 2015 • Visterra, Inc. • Pharmaceutical preparations • Delaware
This Amended and Restated Series B Convertible Preferred Stock Purchase Agreement dated as of September 12, 2014 (this “Agreement”) is made by and among (i) Visterra, Inc., a Delaware corporation (the “Company”), (ii) the persons and entities listed on Schedule 1 hereto (each individually, a “Purchaser” and collectively, the “Purchasers”), (iii) solely for the purposes of Sections 6 through 11 of this Agreement, the “Preferred Holders” (as defined in Section 8.1 below) who are not Purchasers, and, (iv) solely for the purposes of Sections 8 through 11 of this Agreement, the “Founder Holders” (as defined in Section 8.1 below).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. MASSACHUSETTS INSTITUTE OF TECHNOLOGY AND VISTERRA INC. EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • November 4th, 2015 • Visterra, Inc. • Pharmaceutical preparations • Massachusetts
This Agreement, effective as of the date set forth above the signatures of the parties below (the “EFFECTIVE DATE”), is between the Massachusetts Institute of Technology (“M.I.T.”), a Massachusetts corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and Visterra, Inc. (“COMPANY”), a Delaware corporate, with a principal place of business at One Kendall Square, Suite B3301, Cambridge, MA 02139.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. DATED the 27th day of April, 2015 BETWEEN D3 (Drug Discovery & Development) AND Visterra Inc. AGREEMENT FOR RESEARCH...Research Collaboration Agreement • November 4th, 2015 • Visterra, Inc. • Pharmaceutical preparations
D3 (Drug Discovery & Development), Biomedical Sciences Institutes (Co. Registration No. 53239949L), a company incorporated in Singapore and having its principal office at 31 Biopolis Way, 01-02A Nanos, Singapore, 138669 (hereinafter referred to as “D3”) of the first part;
